QR Code

MET Amplification and Efficacy of Nivolumab in Patients With NSCLC

Introduction: MET amplification is an important genetic alteration in NSCLC. Unlike in patients with EGFR and ALK alterations, the efficacy of immune checkpoint inhibitors in patients with MET-amplified NSCLC remains unknown. Methods: An exploratory analysis of a prospective, multi-institutional coh...

Full description

Saved in:
Main Authors: Katsuhiro Yoshimura, MD, PhD, Yusuke Inoue, MD, PhD, Naoki Inui, MD, PhD, Masato Karayama, MD, PhD, Hideki Yasui, MD, PhD, Hironao Hozumi, MD, PhD, Yuzo Suzuki, MD, PhD, Kazuki Furuhashi, MD, PhD, Tomoyuki Fujisawa, MD, PhD, Noriyuki Enomoto, MD, PhD, Yutaro Nakamura, MD, PhD, Haruhiko Sugimura, MD, PhD, Takafumi Suda, MD, PhD
Format: Artigo
Language:Inglês
Published: Elsevier 2021-11-01
Series:JTO Clinical and Research Reports
Subjects:
Lung cancer
MET
Nivolumab
Amplification
Immune checkpoint inhibitor
Online Access:http://www.sciencedirect.com/science/article/pii/S2666364321000989
Tags: Add Tag
No Tags, Be the first to tag this record!

Similar Items